Overview

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.
Phase:
Phase 4
Details
Lead Sponsor:
Galderma Laboratories, L.P.
Treatments:
Doxycycline
Metronidazole